Vis enkel innførsel

dc.contributor.authorHokstad, Ingrid
dc.contributor.authorDeyab, Gia
dc.contributor.authorFagerland, Morten
dc.contributor.authorLyberg, Torstein
dc.contributor.authorHjeltnes, Gunnbjørg
dc.contributor.authorFørre, Øystein Thorleiv
dc.contributor.authorAgewall, Stefan
dc.contributor.authorMollnes, Tom Eirik
dc.contributor.authorHollan, Ivana
dc.date.accessioned2019-09-11T10:28:58Z
dc.date.available2019-09-11T10:28:58Z
dc.date.issued2019-07-23
dc.description.abstract<i>Background</i> - The complement system is involved in pathogenesis of cardiovascular disease, and might play a role in accelerated atherogenesis in spondylarthropathies (SpA). Hence, we examined complement activation in SpA, and its relationship to antirheumatic treatment, inflammatory and cardiovascular markers. <p> <p><i>Methods</i> - From PSARA, a prospective observational study, we examined 51 SpA patients (31 psoriatic arthritis (PsA), and 20 ankylosing spondylitis (AS)), starting tumor necrosis factor (TNF) inhibitor alone (n = 25), combined with methotrexate (MTX) (n = 10), or MTX monotherapy (n = 16). Complement activation was determined by the soluble terminal complement complex (sC5b-9), inflammation by erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), and endothelial function by finger plethysmography (Endopat) at baseline, after 6 weeks and 6 months of treatment. <p> <p><i>Results</i> - SpA patients had sC5b-9 levels at (PsA) or above (AS) the upper limit of the estimated reference range. Median sC5b-9 levels decreased significantly from baseline to 6 weeks, with no significant difference between the AS and PsA group. Notably, a significant reduction in sC5b-9 was observed after administration of TNF inhibitor ± MTX, whereas no significant changes were observed in patients treated with MTX alone. Between 6 weeks and 6 months, sC5b-9 remained stable across all subgroups. Reduction in sC5b-9 was independently related to decreased ESR and CRP, and to increased high density cholesterol and total cholesterol. Reduction in sC5b-9 from baseline to 6 weeks was associated with improved EF in age and gender adjusted analyses. <p> <p><i>Conclusion</i> - TNF-inhibition, but not MTX monotherapy, led to rapid and sustained reduction of complement activation in SpA. Thus, the observed decrease in cardiovascular morbidity in patients treated with TNF-inhibitors might be partly due to its beneficial effect on complement.en_US
dc.description.sponsorshipThe Norwegian Women's Public Health Association The Norwegian Council on Cardiovascular Disease The Odd Fellow Foundation The Simon Fougner Hartmann Family Funden_US
dc.descriptionSource at <a href=https://doi.org/10.1371/journal.pone.0220079>https://doi.org/10.1371/journal.pone.0220079. </a>en_US
dc.identifier.citationHokstad, I., Deyab, G., Fagerland, M.W., Lyberg, T., Hjeltnes, G., Førre, Ø. ... Hollan, I. (2019). Tumor necrosis factor inhibitors are associated with reduced complement activation in spondylarthropathies: An observational study. <i>PLOS ONE, 14</i>(7): e0220079. https://doi.org/10.1371/journal.pone.0220079en_US
dc.identifier.cristinIDFRIDAID 1721155
dc.identifier.doi10.1371/journal.pone.0220079
dc.identifier.issn1932-6203
dc.identifier.urihttps://hdl.handle.net/10037/16159
dc.language.isoengen_US
dc.publisherPublic Library of Scienceen_US
dc.relation.journalPLOS ONE
dc.relation.urihttps://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0220079&type=printable
dc.rights.accessRightsopenAccessen_US
dc.subjectVDP::Medical disciplines: 700::Basic medical, dental and veterinary science disciplines: 710en_US
dc.subjectVDP::Medisinske Fag: 700::Basale medisinske, odontologiske og veterinærmedisinske fag: 710en_US
dc.titleTumor necrosis factor inhibitors are associated with reduced complement activation in spondylarthropathies: An observational studyen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel